Industry Research Reports
Home > Reports > Medical Devices & Consumables > Global Recombinant Human Oncostatin-M(OSM) Market Insights, Forecast to 2031
Global Recombinant Human Oncostatin-M(OSM) Market Insights, Forecast to 2031
Industry: Medical Devices & Consumables
Published Date: 2025-05-10
Pages: 177 Pages
Report ld: 4734173
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Recombinant Human Oncostatin-M(OSM) Market Size(US$)
CAGR 2025-2031
9.0%
Market Size,2031
USD 198
Million
Market Snapshot
Market Size in 2025 (Value)
US$ 118 million
Market Forecast in 2031(Value)
US$ 198 million
CAGR
9.0%
Years Considered
2020-2031
Base Year
2025
Forecast Period
2025-2031
Source: Secondary research, interviews with experts, and QYResearch analysis
The global Recombinant Human Oncostatin-M(OSM) market is projected to grow from US$ 118 million in 2025 to US$ 198 million by 2031, at a Compound Annual Growth Rate (CAGR) of 9.0% during the forecast period.
The evolving U.S. tariff policy posed substantial volatility risks to global markets. This report provides a comprehensive assessment of trade barrier escalations and cross-border counterstrategies, analyzing their multidimensional impacts on industrial competition patterns, geo-economic integration, and transnational value chain realignments.
Oncostatin M (OSM) is a growth differentiation factor involved in the regulation of neurogenesis, osteogenesis, and hematopoiesis. It stimulates the proliferation of fibroblasts, smooth muscle cells, and Kaposi's sarcoma cells, but inhibits the growth of some normal and tumor cell lines. It also promotes the release of cytokines (such as IL-6, GM-CSF, and g-CSF) from endothelial cells and enhances the expression of low-density lipoprotein receptors in hepatoma cells. OSM is produced by activated T cells, monocytes, and Kaposi's sarcoma cells and has stimulatory and inhibitory effects on cell proliferation.
The US & Canada market for Recombinant Human Oncostatin-M(OSM) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Recombinant Human Oncostatin-M(OSM) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Recombinant Human Oncostatin-M(OSM) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global key manufacturers of Recombinant Human Oncostatin-M(OSM) include Thermo Fisher Scientific Inc., Bio-Techne, Scientists Helping Scientists, Abcam Limited, FUJIFILM Irvine Scientific, BD Biosciences, Bio-Rad Laboratories, Inc., BPS Bioscience, Inc., Elabscience, Yisheng Biotechnology (Shanghai) Co., Ltd., etc. In 2024, the global top five players had a share approximately % in terms of revenue.
In terms of consumption side, this report focuses on the sales of Recombinant Human Oncostatin-M(OSM) by region (region level and country level), by company, by Type and by Application. from 2020 to 2025 and forecast to 2031.
This report presents an overview of global market for Recombinant Human Oncostatin-M(OSM), capacity, output, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2020 - 2025, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Recombinant Human Oncostatin-M(OSM), also provides the consumption of main regions and countries. Highlights of the upcoming market potential for Recombinant Human Oncostatin-M(OSM), and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Recombinant Human Oncostatin-M(OSM) sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Recombinant Human Oncostatin-M(OSM) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Recombinant Human Oncostatin-M(OSM) sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Thermo Fisher Scientific Inc., Bio-Techne, Scientists Helping Scientists, Abcam Limited, FUJIFILM Irvine Scientific, BD Biosciences, Bio-Rad Laboratories, Inc., BPS Bioscience, Inc., Elabscience, Yisheng Biotechnology (Shanghai) Co., Ltd., etc.
MARKET SEGMENTATION
By Company
- Thermo Fisher Scientific Inc.
- Bio-Techne
- Scientists Helping Scientists
- Abcam Limited
- FUJIFILM Irvine Scientific
- BD Biosciences
- Bio-Rad Laboratories, Inc.
- BPS Bioscience, Inc.
- Elabscience
- Yisheng Biotechnology (Shanghai) Co., Ltd.
- ENZO
- Beijing Biocreative Technology Co., Ltd.
- Shanghai Yaji Biotechnology Co., Ltd.
- Cellverse Co., Ltd.
- Dalian Meilun Biotech Co., Ltd.
- Sino Biological,Inc.
- Prospec-Tany Technogene Ltd
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Purity＜95%
- Purity ≥95%
Segment by Application
- University
- Research Center
CHAPTER OUTLINE
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Recombinant Human Oncostatin-M(OSM) in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Recombinant Human Oncostatin-M(OSM) manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Recombinant Human Oncostatin-M(OSM) sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Study Coverage
1.1 Recombinant Human Oncostatin-M(OSM) Product Introduction
1.2 Market by Type
1.2.1 Global Recombinant Human Oncostatin-M(OSM) Market Size Growth Rate by Type, 2020 VS 2024 VS 2031
1.2.2 Purity＜95%
1.2.3 Purity ≥95%
1.3 Market by Application
1.3.1 Global Recombinant Human Oncostatin-M(OSM) Market Size Growth Rate by Application, 2020 VS 2024 VS 2031
1.3.2 University
1.3.3 Research Center
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Recombinant Human Oncostatin-M(OSM) Revenue Estimates and Forecasts 2020-2031
2.2 Global Revenue by Region
2.2.1 Global Recombinant Human Oncostatin-M(OSM) Revenue by Region: 2020 VS 2024 VS 2031
2.2.2 Global Recombinant Human Oncostatin-M(OSM) Revenue by Region (2020-2031)
2.2.3 Global Recombinant Human Oncostatin-M(OSM) Revenue Market Share by Region (2020-2031)
2.3 Global Recombinant Human Oncostatin-M(OSM) Sales Estimates and Forecasts 2020-2031
2.4 Global Sales by Region
2.4.1 Global Recombinant Human Oncostatin-M(OSM) Sales by Region: 2020 VS 2024 VS 2031
2.4.2 Global Recombinant Human Oncostatin-M(OSM) Sales by Region (2020-2031)
2.4.3 Global Recombinant Human Oncostatin-M(OSM) Sales Market Share by Region (2020-2031)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Sales by Manufacturers
3.1.1 Global Recombinant Human Oncostatin-M(OSM) Sales by Manufacturers (2020-2025)
3.1.2 Global Recombinant Human Oncostatin-M(OSM) Sales Market Share by Manufacturers (2020-2025)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Recombinant Human Oncostatin-M(OSM) in 2024
3.2 Global Revenue by Manufacturers
3.2.1 Global Recombinant Human Oncostatin-M(OSM) Revenue by Manufacturers (2020-2025)
3.2.2 Global Recombinant Human Oncostatin-M(OSM) Revenue Market Share by Manufacturers (2020-2025)
3.2.3 Global Top 10 and Top 5 Companies by Recombinant Human Oncostatin-M(OSM) Revenue in 2024
3.3 Global Key Players of Recombinant Human Oncostatin-M(OSM), Industry Ranking, 2023 VS 2024
3.4 Global Recombinant Human Oncostatin-M(OSM) Sales Price by Manufacturers (2020-2025)
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Recombinant Human Oncostatin-M(OSM) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Recombinant Human Oncostatin-M(OSM), Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Recombinant Human Oncostatin-M(OSM), Product Offered and Application
3.8 Global Key Manufacturers of Recombinant Human Oncostatin-M(OSM), Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Sales by Type
4.1.1 Global Recombinant Human Oncostatin-M(OSM) Historical Sales by Type (2020-2025)
4.1.2 Global Recombinant Human Oncostatin-M(OSM) Forecasted Sales by Type (2026-2031)
4.1.3 Global Recombinant Human Oncostatin-M(OSM) Sales Market Share by Type (2020-2031)
4.2 Global Revenue by Type
4.2.1 Global Recombinant Human Oncostatin-M(OSM) Historical Revenue by Type (2020-2025)
4.2.2 Global Recombinant Human Oncostatin-M(OSM) Forecasted Revenue by Type (2026-2031)
4.2.3 Global Recombinant Human Oncostatin-M(OSM) Revenue Market Share by Type (2020-2031)
4.3 Global Price by Type
4.3.1 Global Recombinant Human Oncostatin-M(OSM) Price by Type (2020-2025)
4.3.2 Global Recombinant Human Oncostatin-M(OSM) Price Forecast by Type (2026-2031)
5 Market Size by Application
5.1 Global Sales by Application
5.1.1 Global Recombinant Human Oncostatin-M(OSM) Historical Sales by Application (2020-2025)
5.1.2 Global Recombinant Human Oncostatin-M(OSM) Forecasted Sales by Application (2026-2031)
5.1.3 Global Recombinant Human Oncostatin-M(OSM) Sales Market Share by Application (2020-2031)
5.2 Global Revenue by Application
5.2.1 Global Recombinant Human Oncostatin-M(OSM) Historical Revenue by Application (2020-2025)
5.2.2 Global Recombinant Human Oncostatin-M(OSM) Forecasted Revenue by Application (2026-2031)
5.2.3 Global Recombinant Human Oncostatin-M(OSM) Revenue Market Share by Application (2020-2031)
5.3 Global Price by Application
5.3.1 Global Recombinant Human Oncostatin-M(OSM) Price by Application (2020-2025)
5.3.2 Global Recombinant Human Oncostatin-M(OSM) Price Forecast by Application (2026-2031)
6 US & Canada
6.1 US & Canada Market Size by Type
6.1.1 US & Canada Recombinant Human Oncostatin-M(OSM) Sales by Type (2020-2031)
6.1.2 US & Canada Recombinant Human Oncostatin-M(OSM) Revenue by Type (2020-2031)
6.2 US & Canada Market Size by Application
6.2.1 US & Canada Recombinant Human Oncostatin-M(OSM) Sales by Application (2020-2031)
6.2.2 US & Canada Recombinant Human Oncostatin-M(OSM) Revenue by Application (2020-2031)
6.3 US & Canada Market Size by Country
6.3.1 US & Canada Recombinant Human Oncostatin-M(OSM) Revenue by Country: 2020 VS 2024 VS 2031
6.3.2 US & Canada Recombinant Human Oncostatin-M(OSM) Revenue by Country (2020-2031)
6.3.3 US & Canada Recombinant Human Oncostatin-M(OSM) Sales by Country (2020-2031)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Market Size by Type
7.1.1 Europe Recombinant Human Oncostatin-M(OSM) Sales by Type (2020-2031)
7.1.2 Europe Recombinant Human Oncostatin-M(OSM) Revenue by Type (2020-2031)
7.2 Europe Market Size by Application
7.2.1 Europe Recombinant Human Oncostatin-M(OSM) Sales by Application (2020-2031)
7.2.2 Europe Recombinant Human Oncostatin-M(OSM) Revenue by Application (2020-2031)
7.3 Europe Market Size by Country
7.3.1 Europe Recombinant Human Oncostatin-M(OSM) Revenue by Country: 2020 VS 2024 VS 2031
7.3.2 Europe Recombinant Human Oncostatin-M(OSM) Sales by Country (2020-2031)
7.3.3 Europe Recombinant Human Oncostatin-M(OSM) Revenue by Country (2020-2031)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Market Size by Type
8.1.1 China Recombinant Human Oncostatin-M(OSM) Sales by Type (2020-2031)
8.1.2 China Recombinant Human Oncostatin-M(OSM) Revenue by Type (2020-2031)
8.2 China Market Size by Application
8.2.1 China Recombinant Human Oncostatin-M(OSM) Sales by Application (2020-2031)
8.2.2 China Recombinant Human Oncostatin-M(OSM) Revenue by Application (2020-2031)
9 Asia (excluding China)
9.1 Asia Market Size by Type
9.1.1 Asia Recombinant Human Oncostatin-M(OSM) Sales by Type (2020-2031)
9.1.2 Asia Recombinant Human Oncostatin-M(OSM) Revenue by Type (2020-2031)
9.2 Asia Market Size by Application
9.2.1 Asia Recombinant Human Oncostatin-M(OSM) Sales by Application (2020-2031)
9.2.2 Asia Recombinant Human Oncostatin-M(OSM) Revenue by Application (2020-2031)
9.3 Asia Market Size by Region
9.3.1 Asia Recombinant Human Oncostatin-M(OSM) Revenue by Region: 2020 VS 2024 VS 2031
9.3.2 Asia Recombinant Human Oncostatin-M(OSM) Revenue by Region (2020-2031)
9.3.3 Asia Recombinant Human Oncostatin-M(OSM) Sales by Region (2020-2031)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
9.3.9 Australia
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Market Size by Type
10.1.1 Middle East, Africa and Latin America Recombinant Human Oncostatin-M(OSM) Sales by Type (2020-2031)
10.1.2 Middle East, Africa and Latin America Recombinant Human Oncostatin-M(OSM) Revenue by Type (2020-2031)
10.2 Middle East, Africa and Latin America Market Size by Application
10.2.1 Middle East, Africa and Latin America Recombinant Human Oncostatin-M(OSM) Sales by Application (2020-2031)
10.2.2 Middle East, Africa and Latin America Recombinant Human Oncostatin-M(OSM) Revenue by Application (2020-2031)
10.3 Middle East, Africa and Latin America Market Size by Country
10.3.1 Middle East, Africa and Latin America Recombinant Human Oncostatin-M(OSM) Revenue by Country: 2020 VS 2024 VS 2031
10.3.2 Middle East, Africa and Latin America Recombinant Human Oncostatin-M(OSM) Revenue by Country (2020-2031)
10.3.3 Middle East, Africa and Latin America Recombinant Human Oncostatin-M(OSM) Sales by Country (2020-2031)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Corporate Profile
11.1 Thermo Fisher Scientific Inc.
11.1.1 Thermo Fisher Scientific Inc. Company Information
11.1.2 Thermo Fisher Scientific Inc. Overview
11.1.3 Thermo Fisher Scientific Inc. Recombinant Human Oncostatin-M(OSM) Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.4 Thermo Fisher Scientific Inc. Recombinant Human Oncostatin-M(OSM) Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Thermo Fisher Scientific Inc. Recent Developments
11.2 Bio-Techne
11.2.1 Bio-Techne Company Information
11.2.2 Bio-Techne Overview
11.2.3 Bio-Techne Recombinant Human Oncostatin-M(OSM) Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.4 Bio-Techne Recombinant Human Oncostatin-M(OSM) Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Bio-Techne Recent Developments
11.3 Scientists Helping Scientists
11.3.1 Scientists Helping Scientists Company Information
11.3.2 Scientists Helping Scientists Overview
11.3.3 Scientists Helping Scientists Recombinant Human Oncostatin-M(OSM) Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.4 Scientists Helping Scientists Recombinant Human Oncostatin-M(OSM) Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Scientists Helping Scientists Recent Developments
11.4 Abcam Limited
11.4.1 Abcam Limited Company Information
11.4.2 Abcam Limited Overview
11.4.3 Abcam Limited Recombinant Human Oncostatin-M(OSM) Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.4 Abcam Limited Recombinant Human Oncostatin-M(OSM) Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Abcam Limited Recent Developments
11.5 FUJIFILM Irvine Scientific
11.5.1 FUJIFILM Irvine Scientific Company Information
11.5.2 FUJIFILM Irvine Scientific Overview
11.5.3 FUJIFILM Irvine Scientific Recombinant Human Oncostatin-M(OSM) Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.4 FUJIFILM Irvine Scientific Recombinant Human Oncostatin-M(OSM) Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 FUJIFILM Irvine Scientific Recent Developments
11.6 BD Biosciences
11.6.1 BD Biosciences Company Information
11.6.2 BD Biosciences Overview
11.6.3 BD Biosciences Recombinant Human Oncostatin-M(OSM) Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.4 BD Biosciences Recombinant Human Oncostatin-M(OSM) Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 BD Biosciences Recent Developments
11.7 Bio-Rad Laboratories, Inc.
11.7.1 Bio-Rad Laboratories, Inc. Company Information
11.7.2 Bio-Rad Laboratories, Inc. Overview
11.7.3 Bio-Rad Laboratories, Inc. Recombinant Human Oncostatin-M(OSM) Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.4 Bio-Rad Laboratories, Inc. Recombinant Human Oncostatin-M(OSM) Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Bio-Rad Laboratories, Inc. Recent Developments
11.8 BPS Bioscience, Inc.
11.8.1 BPS Bioscience, Inc. Company Information
11.8.2 BPS Bioscience, Inc. Overview
11.8.3 BPS Bioscience, Inc. Recombinant Human Oncostatin-M(OSM) Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.4 BPS Bioscience, Inc. Recombinant Human Oncostatin-M(OSM) Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 BPS Bioscience, Inc. Recent Developments
11.9 Elabscience
11.9.1 Elabscience Company Information
11.9.2 Elabscience Overview
11.9.3 Elabscience Recombinant Human Oncostatin-M(OSM) Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.4 Elabscience Recombinant Human Oncostatin-M(OSM) Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Elabscience Recent Developments
11.10 Yisheng Biotechnology (Shanghai) Co., Ltd.
11.10.1 Yisheng Biotechnology (Shanghai) Co., Ltd. Company Information
11.10.2 Yisheng Biotechnology (Shanghai) Co., Ltd. Overview
11.10.3 Yisheng Biotechnology (Shanghai) Co., Ltd. Recombinant Human Oncostatin-M(OSM) Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.4 Yisheng Biotechnology (Shanghai) Co., Ltd. Recombinant Human Oncostatin-M(OSM) Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Yisheng Biotechnology (Shanghai) Co., Ltd. Recent Developments
11.11 ENZO
11.11.1 ENZO Company Information
11.11.2 ENZO Overview
11.11.3 ENZO Recombinant Human Oncostatin-M(OSM) Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.4 ENZO Recombinant Human Oncostatin-M(OSM) Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 ENZO Recent Developments
11.12 Beijing Biocreative Technology Co., Ltd.
11.12.1 Beijing Biocreative Technology Co., Ltd. Company Information
11.12.2 Beijing Biocreative Technology Co., Ltd. Overview
11.12.3 Beijing Biocreative Technology Co., Ltd. Recombinant Human Oncostatin-M(OSM) Sales, Price, Revenue and Gross Margin (2020-2025)
11.12.4 Beijing Biocreative Technology Co., Ltd. Recombinant Human Oncostatin-M(OSM) Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Beijing Biocreative Technology Co., Ltd. Recent Developments
11.13 Shanghai Yaji Biotechnology Co., Ltd.
11.13.1 Shanghai Yaji Biotechnology Co., Ltd. Company Information
11.13.2 Shanghai Yaji Biotechnology Co., Ltd. Overview
11.13.3 Shanghai Yaji Biotechnology Co., Ltd. Recombinant Human Oncostatin-M(OSM) Sales, Price, Revenue and Gross Margin (2020-2025)
11.13.4 Shanghai Yaji Biotechnology Co., Ltd. Recombinant Human Oncostatin-M(OSM) Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Shanghai Yaji Biotechnology Co., Ltd. Recent Developments
11.14 Cellverse Co., Ltd.
11.14.1 Cellverse Co., Ltd. Company Information
11.14.2 Cellverse Co., Ltd. Overview
11.14.3 Cellverse Co., Ltd. Recombinant Human Oncostatin-M(OSM) Sales, Price, Revenue and Gross Margin (2020-2025)
11.14.4 Cellverse Co., Ltd. Recombinant Human Oncostatin-M(OSM) Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Cellverse Co., Ltd. Recent Developments
11.15 Dalian Meilun Biotech Co., Ltd.
11.15.1 Dalian Meilun Biotech Co., Ltd. Company Information
11.15.2 Dalian Meilun Biotech Co., Ltd. Overview
11.15.3 Dalian Meilun Biotech Co., Ltd. Recombinant Human Oncostatin-M(OSM) Sales, Price, Revenue and Gross Margin (2020-2025)
11.15.4 Dalian Meilun Biotech Co., Ltd. Recombinant Human Oncostatin-M(OSM) Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Dalian Meilun Biotech Co., Ltd. Recent Developments
11.16 Sino Biological,Inc.
11.16.1 Sino Biological,Inc. Company Information
11.16.2 Sino Biological,Inc. Overview
11.16.3 Sino Biological,Inc. Recombinant Human Oncostatin-M(OSM) Sales, Price, Revenue and Gross Margin (2020-2025)
11.16.4 Sino Biological,Inc. Recombinant Human Oncostatin-M(OSM) Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Sino Biological,Inc. Recent Developments
11.17 Prospec-Tany Technogene Ltd
11.17.1 Prospec-Tany Technogene Ltd Company Information
11.17.2 Prospec-Tany Technogene Ltd Overview
11.17.3 Prospec-Tany Technogene Ltd Recombinant Human Oncostatin-M(OSM) Sales, Price, Revenue and Gross Margin (2020-2025)
11.17.4 Prospec-Tany Technogene Ltd Recombinant Human Oncostatin-M(OSM) Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 Prospec-Tany Technogene Ltd Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Recombinant Human Oncostatin-M(OSM) Industry Chain Analysis
12.2 Recombinant Human Oncostatin-M(OSM) Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Recombinant Human Oncostatin-M(OSM) Production Mode & Process
12.4 Recombinant Human Oncostatin-M(OSM) Sales and Marketing
12.4.1 Recombinant Human Oncostatin-M(OSM) Sales Channels
12.4.2 Recombinant Human Oncostatin-M(OSM) Distributors
12.5 Recombinant Human Oncostatin-M(OSM) Customers
13 Recombinant Human Oncostatin-M(OSM) Market Dynamics
13.1 Recombinant Human Oncostatin-M(OSM) Industry Trends
13.2 Recombinant Human Oncostatin-M(OSM) Market Drivers
13.3 Recombinant Human Oncostatin-M(OSM) Market Challenges
13.4 Recombinant Human Oncostatin-M(OSM) Market Restraints
14 Key Findings in the Global Recombinant Human Oncostatin-M(OSM) Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
15.3 Disclaimer
TABLE OF FIGURES
List of Tables
Table 1. Global Recombinant Human Oncostatin-M(OSM) Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Major Manufacturers of Purity＜95%
Table 3. Major Manufacturers of Purity ≥95%
Table 4. Global Recombinant Human Oncostatin-M(OSM) Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 5. Global Recombinant Human Oncostatin-M(OSM) Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 6. Global Revenue by Region (2020-2025) & (US$ Million)
Table 7. Global Revenue Market Share by Region (2020-2031)
Table 8. Global Recombinant Human Oncostatin-M(OSM) Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 9. Global Recombinant Human Oncostatin-M(OSM) Sales by Region (2020-2031) & (K Units)
Table 10. Global Sales Market Share by Region (2020-2031)
Table 11. Global Recombinant Human Oncostatin-M(OSM) Sales by Manufacturers (2020-2025) & (K Units)
Table 12. Global Recombinant Human Oncostatin-M(OSM) Sales Share by Manufacturers (2020-2025)
Table 13. Global Recombinant Human Oncostatin-M(OSM) Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 14. Global Recombinant Human Oncostatin-M(OSM) Revenue Market Share by Manufacturers (2020-2025)
Table 15. Global Key Players of Recombinant Human Oncostatin-M(OSM), Industry Ranking, 2023 VS 2024 VS 2024
Table 16. Recombinant Human Oncostatin-M(OSM) Price by Manufacturers (2020-2025) & (US$/Unit)
Table 17. Global Recombinant Human Oncostatin-M(OSM) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 18. Global Recombinant Human Oncostatin-M(OSM) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Human Oncostatin-M(OSM) as of 2024)
Table 19. Global Key Manufacturers of Recombinant Human Oncostatin-M(OSM), Manufacturing Base Distribution and Headquarters
Table 20. Global Key Manufacturers of Recombinant Human Oncostatin-M(OSM), Product Offered and Application
Table 21. Global Key Manufacturers of Recombinant Human Oncostatin-M(OSM), Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Recombinant Human Oncostatin-M(OSM) Sales by Type (2020-2025) & (K Units)
Table 24. Global Recombinant Human Oncostatin-M(OSM) Sales by Type (2026-2031) & (K Units)
Table 25. Global Sales Share by Type (2020-2031)
Table 26. Global Recombinant Human Oncostatin-M(OSM) Revenue by Type (2020-2025) & (US$ Million)
Table 27. Global Recombinant Human Oncostatin-M(OSM) Revenue by Type (2026-2031) & (US$ Million)
Table 28. Global Revenue Share by Type (2020-2031)
Table 29. Recombinant Human Oncostatin-M(OSM) Price by Type (2020-2025) & (US$/Unit)
Table 30. Global Recombinant Human Oncostatin-M(OSM) Price Forecast by Type (2026-2031) & (US$/Unit)
Table 31. Global Recombinant Human Oncostatin-M(OSM) Sales by Application (2020-2025) & (K Units)
Table 32. Global Recombinant Human Oncostatin-M(OSM) Sales by Application (2026-2031) & (K Units)
Table 33. Global Sales Share by Application (2020-2031)
Table 34. Global Recombinant Human Oncostatin-M(OSM) Revenue by Application (2020-2025) & (US$ Million)
Table 35. Global Recombinant Human Oncostatin-M(OSM) Revenue by Application (2026-2031) & (US$ Million)
Table 36. Global Revenue Share by Application (2020-2031)
Table 37. Recombinant Human Oncostatin-M(OSM) Price by Application (2020-2025) & (US$/Unit)
Table 38. Global Recombinant Human Oncostatin-M(OSM) Price Forecast by Application (2026-2031) & (US$/Unit)
Table 39. US & Canada Sales by Type (2020-2031) & (K Units)
Table 40. US & Canada Revenue by Type (2020-2031) & (US$ Million)
Table 41. US & Canada Sales by Application (2020-2031) & (K Units)
Table 42. US & Canada Revenue by Application (2020-2031) & (US$ Million)
Table 43. US & Canada Recombinant Human Oncostatin-M(OSM) Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 44. US & Canada Revenue by Country (2020-2031) & (US$ Million)
Table 45. US & Canada Sales by Country (2020-2031) & (K Units)
Table 46. Europe Sales by Type (2020-2031) & (K Units)
Table 47. Europe Revenue by Type (2020-2031) & (US$ Million)
Table 48. Europe Sales by Application (2020-2031) & (K Units)
Table 49. Europe Revenue by Application (2020-2031) & (US$ Million)
Table 50. Europe Recombinant Human Oncostatin-M(OSM) Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 51. Europe Sales by Country (2020-2031) & (K Units)
Table 52. Europe Revenue by Country (2020-2031) & (US$ Million)
Table 53. China Sales by Type (2020-2031) & (K Units)
Table 54. China Revenue by Type (2020-2031) & (US$ Million)
Table 55. China Sales by Application (2020-2031) & (K Units)
Table 56. China Revenue by Application (2020-2031) & (US$ Million)
Table 57. Asia Sales by Type (2020-2031) & (K Units)
Table 58. Asia Revenue by Type (2020-2031) & (US$ Million)
Table 59. Asia Sales by Application (2020-2031) & (K Units)
Table 60. Asia Revenue by Application (2020-2031) & (US$ Million)
Table 61. Asia Recombinant Human Oncostatin-M(OSM) Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 62. Asia Revenue by Region (2020-2031) & (US$ Million)
Table 63. Asia Sales by Region (2020-2031) & (K Units)
Table 64. Middle East, Africa and Latin America Sales by Type (2020-2031) & (K Units)
Table 65. Middle East, Africa and Latin America Revenue by Type (2020-2031) & (US$ Million)
Table 66. Middle East, Africa and Latin America Sales by Application (2020-2031) & (K Units)
Table 67. Middle East, Africa and Latin America Revenue by Application (2020-2031) & (US$ Million)
Table 68. Middle East, Africa and Latin America Recombinant Human Oncostatin-M(OSM) Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 69. Middle East, Africa and Latin America Revenue by Country (2020-2031) & (US$ Million)
Table 70. Middle East, Africa and Latin America Sales by Country (2020-2031) & (K Units)
Table 71. Thermo Fisher Scientific Inc. Company Information
Table 72. Thermo Fisher Scientific Inc. Description and Major Businesses
Table 73. Thermo Fisher Scientific Inc. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 74. Thermo Fisher Scientific Inc. Product Model Numbers, Pictures, Descriptions and Specifications
Table 75. Thermo Fisher Scientific Inc. Recent Developments
Table 76. Bio-Techne Company Information
Table 77. Bio-Techne Description and Major Businesses
Table 78. Bio-Techne Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 79. Bio-Techne Product Model Numbers, Pictures, Descriptions and Specifications
Table 80. Bio-Techne Recent Developments
Table 81. Scientists Helping Scientists Company Information
Table 82. Scientists Helping Scientists Description and Major Businesses
Table 83. Scientists Helping Scientists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 84. Scientists Helping Scientists Product Model Numbers, Pictures, Descriptions and Specifications
Table 85. Scientists Helping Scientists Recent Developments
Table 86. Abcam Limited Company Information
Table 87. Abcam Limited Description and Major Businesses
Table 88. Abcam Limited Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 89. Abcam Limited Product Model Numbers, Pictures, Descriptions and Specifications
Table 90. Abcam Limited Recent Developments
Table 91. FUJIFILM Irvine Scientific Company Information
Table 92. FUJIFILM Irvine Scientific Description and Major Businesses
Table 93. FUJIFILM Irvine Scientific Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 94. FUJIFILM Irvine Scientific Product Model Numbers, Pictures, Descriptions and Specifications
Table 95. FUJIFILM Irvine Scientific Recent Developments
Table 96. BD Biosciences Company Information
Table 97. BD Biosciences Description and Major Businesses
Table 98. BD Biosciences Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. BD Biosciences Product Model Numbers, Pictures, Descriptions and Specifications
Table 100. BD Biosciences Recent Developments
Table 101. Bio-Rad Laboratories, Inc. Company Information
Table 102. Bio-Rad Laboratories, Inc. Description and Major Businesses
Table 103. Bio-Rad Laboratories, Inc. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Bio-Rad Laboratories, Inc. Product Model Numbers, Pictures, Descriptions and Specifications
Table 105. Bio-Rad Laboratories, Inc. Recent Developments
Table 106. BPS Bioscience, Inc. Company Information
Table 107. BPS Bioscience, Inc. Description and Major Businesses
Table 108. BPS Bioscience, Inc. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. BPS Bioscience, Inc. Product Model Numbers, Pictures, Descriptions and Specifications
Table 110. BPS Bioscience, Inc. Recent Developments
Table 111. Elabscience Company Information
Table 112. Elabscience Description and Major Businesses
Table 113. Elabscience Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. Elabscience Product Model Numbers, Pictures, Descriptions and Specifications
Table 115. Elabscience Recent Developments
Table 116. Yisheng Biotechnology (Shanghai) Co., Ltd. Company Information
Table 117. Yisheng Biotechnology (Shanghai) Co., Ltd. Description and Major Businesses
Table 118. Yisheng Biotechnology (Shanghai) Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. Yisheng Biotechnology (Shanghai) Co., Ltd. Product Model Numbers, Pictures, Descriptions and Specifications
Table 120. Yisheng Biotechnology (Shanghai) Co., Ltd. Recent Developments
Table 121. ENZO Company Information
Table 122. ENZO Description and Major Businesses
Table 123. ENZO Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 124. ENZO Product Model Numbers, Pictures, Descriptions and Specifications
Table 125. ENZO Recent Developments
Table 126. Beijing Biocreative Technology Co., Ltd. Company Information
Table 127. Beijing Biocreative Technology Co., Ltd. Description and Major Businesses
Table 128. Beijing Biocreative Technology Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 129. Beijing Biocreative Technology Co., Ltd. Product Model Numbers, Pictures, Descriptions and Specifications
Table 130. Beijing Biocreative Technology Co., Ltd. Recent Developments
Table 131. Shanghai Yaji Biotechnology Co., Ltd. Company Information
Table 132. Shanghai Yaji Biotechnology Co., Ltd. Description and Major Businesses
Table 133. Shanghai Yaji Biotechnology Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 134. Shanghai Yaji Biotechnology Co., Ltd. Product Model Numbers, Pictures, Descriptions and Specifications
Table 135. Shanghai Yaji Biotechnology Co., Ltd. Recent Developments
Table 136. Cellverse Co., Ltd. Company Information
Table 137. Cellverse Co., Ltd. Description and Major Businesses
Table 138. Cellverse Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 139. Cellverse Co., Ltd. Product Model Numbers, Pictures, Descriptions and Specifications
Table 140. Cellverse Co., Ltd. Recent Developments
Table 141. Dalian Meilun Biotech Co., Ltd. Company Information
Table 142. Dalian Meilun Biotech Co., Ltd. Description and Major Businesses
Table 143. Dalian Meilun Biotech Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 144. Dalian Meilun Biotech Co., Ltd. Product Model Numbers, Pictures, Descriptions and Specifications
Table 145. Dalian Meilun Biotech Co., Ltd. Recent Developments
Table 146. Sino Biological,Inc. Company Information
Table 147. Sino Biological,Inc. Description and Major Businesses
Table 148. Sino Biological,Inc. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 149. Sino Biological,Inc. Product Model Numbers, Pictures, Descriptions and Specifications
Table 150. Sino Biological,Inc. Recent Developments
Table 151. Prospec-Tany Technogene Ltd Company Information
Table 152. Prospec-Tany Technogene Ltd Description and Major Businesses
Table 153. Prospec-Tany Technogene Ltd Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 154. Prospec-Tany Technogene Ltd Product Model Numbers, Pictures, Descriptions and Specifications
Table 155. Prospec-Tany Technogene Ltd Recent Developments
Table 156. Key Raw Materials Lists
Table 157. Raw Materials Key Suppliers Lists
Table 158. Distributors List
Table 159. Customers List
Table 160. Market Trends
Table 161. Market Drivers
Table 162. Market Challenges
Table 163. Market Restraints
Table 164. Research Programs/Design for This Report
Table 165. Key Data Information from Secondary Sources
Table 166. Key Data Information from Primary Sources
List of Figures
Figure 1. Recombinant Human Oncostatin-M(OSM) Product Picture
Figure 2. Global Recombinant Human Oncostatin-M(OSM) Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Global Recombinant Human Oncostatin-M(OSM) Market Share by Type: 2024 & 2031
Figure 4. Purity＜95% Product Picture
Figure 5. Purity ≥95% Product Picture
Figure 6. Global Recombinant Human Oncostatin-M(OSM) Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Global Recombinant Human Oncostatin-M(OSM) Market Share by Application: 2024 & 2031
Figure 8. University
Figure 9. Research Center
Figure 10. Recombinant Human Oncostatin-M(OSM) Report Years Considered
Figure 11. Global Recombinant Human Oncostatin-M(OSM) Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Recombinant Human Oncostatin-M(OSM) Revenue (2020-2031) & (US$ Million)
Figure 13. Global Recombinant Human Oncostatin-M(OSM) Revenue by Region (2020-2031) (US$ Million)
Figure 14. Global Recombinant Human Oncostatin-M(OSM) Revenue Market Share by Region in Percentage: 2024 Versus 2031
Figure 15. Global Recombinant Human Oncostatin-M(OSM) Revenue Market Share by Region (2020-2031)
Figure 16. Global Recombinant Human Oncostatin-M(OSM) Sales (2020-2031) & (K Units)
Figure 17. Global Recombinant Human Oncostatin-M(OSM) Sales (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Figure 18. Global Recombinant Human Oncostatin-M(OSM) Sales Market Share by Region (2020-2031)
Figure 19. US & Canada Recombinant Human Oncostatin-M(OSM) Sales YoY (2020-2031) & (K Units)
Figure 20. US & Canada Recombinant Human Oncostatin-M(OSM) Revenue YoY (2020-2031) & (US$ Million)
Figure 21. Europe Recombinant Human Oncostatin-M(OSM) Sales YoY (2020-2031) & (K Units)
Figure 22. Europe Recombinant Human Oncostatin-M(OSM) Revenue YoY (2020-2031) & (US$ Million)
Figure 23. China Recombinant Human Oncostatin-M(OSM) Sales YoY (2020-2031) & (K Units)
Figure 24. China Recombinant Human Oncostatin-M(OSM) Revenue YoY (2020-2031) & (US$ Million)
Figure 25. Asia (excluding China) Recombinant Human Oncostatin-M(OSM) Sales YoY (2020-2031) & (K Units)
Figure 26. Asia (excluding China) Recombinant Human Oncostatin-M(OSM) Revenue YoY (2020-2031) & (US$ Million)
Figure 27. Middle East, Africa and Latin America Recombinant Human Oncostatin-M(OSM) Sales YoY (2020-2031) & (K Units)
Figure 28. Middle East, Africa and Latin America Recombinant Human Oncostatin-M(OSM) Revenue YoY (2020-2031) & (US$ Million)
Figure 29. Global Recombinant Human Oncostatin-M(OSM) Sales Share by Manufacturers (2024)
Figure 30. The Recombinant Human Oncostatin-M(OSM) Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2024
Figure 31. Global Recombinant Human Oncostatin-M(OSM) Revenue Share by Manufacturers (2024)
Figure 32. The Top 5 and 10 Largest Manufacturers of Recombinant Human Oncostatin-M(OSM) in the World: Market Share by Recombinant Human Oncostatin-M(OSM) Revenue in 2024
Figure 33. Global Recombinant Human Oncostatin-M(OSM) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 34. Global Recombinant Human Oncostatin-M(OSM) Sales Market Share by Type (2020-2031)
Figure 35. Global Recombinant Human Oncostatin-M(OSM) Revenue Market Share by Type (2020-2031)
Figure 36. Global Recombinant Human Oncostatin-M(OSM) Sales Market Share by Application (2020-2031)
Figure 37. Global Recombinant Human Oncostatin-M(OSM) Revenue Market Share by Application (2020-2031)
Figure 38. US & Canada Recombinant Human Oncostatin-M(OSM) Sales Market Share by Type (2020-2031)
Figure 39. US & Canada Recombinant Human Oncostatin-M(OSM) Revenue Market Share by Type (2020-2031)
Figure 40. US & Canada Recombinant Human Oncostatin-M(OSM) Sales Market Share by Application (2020-2031)
Figure 41. US & Canada Recombinant Human Oncostatin-M(OSM) Revenue Market Share by Application (2020-2031)
Figure 42. US & Canada Recombinant Human Oncostatin-M(OSM) Revenue Share by Country (2020-2031)
Figure 43. US & Canada Recombinant Human Oncostatin-M(OSM) Sales Share by Country (2020-2031)
Figure 44. US Recombinant Human Oncostatin-M(OSM) Revenue (2020-2031) & (US$ Million)
Figure 45. Canada Recombinant Human Oncostatin-M(OSM) Revenue (2020-2031) & (US$ Million)
Figure 46. Europe Recombinant Human Oncostatin-M(OSM) Sales Market Share by Type (2020-2031)
Figure 47. Europe Recombinant Human Oncostatin-M(OSM) Revenue Market Share by Type (2020-2031)
Figure 48. Europe Recombinant Human Oncostatin-M(OSM) Sales Market Share by Application (2020-2031)
Figure 49. Europe Recombinant Human Oncostatin-M(OSM) Revenue Market Share by Application (2020-2031)
Figure 50. Europe Recombinant Human Oncostatin-M(OSM) Sales Share by Country (2020-2031)
Figure 51. Europe Recombinant Human Oncostatin-M(OSM) Revenue Share by Country (2020-2031)
Figure 52. Germany Recombinant Human Oncostatin-M(OSM) Revenue (2020-2031) & (US$ Million)
Figure 53. France Recombinant Human Oncostatin-M(OSM) Revenue (2020-2031) & (US$ Million)
Figure 54. U.K. Recombinant Human Oncostatin-M(OSM) Revenue (2020-2031) & (US$ Million)
Figure 55. Italy Recombinant Human Oncostatin-M(OSM) Revenue (2020-2031) & (US$ Million)
Figure 56. Russia Recombinant Human Oncostatin-M(OSM) Revenue (2020-2031) & (US$ Million)
Figure 57. China Recombinant Human Oncostatin-M(OSM) Sales Market Share by Type (2020-2031)
Figure 58. China Recombinant Human Oncostatin-M(OSM) Revenue Market Share by Type (2020-2031)
Figure 59. China Recombinant Human Oncostatin-M(OSM) Sales Market Share by Application (2020-2031)
Figure 60. China Recombinant Human Oncostatin-M(OSM) Revenue Market Share by Application (2020-2031)
Figure 61. Asia Recombinant Human Oncostatin-M(OSM) Sales Market Share by Type (2020-2031)
Figure 62. Asia Recombinant Human Oncostatin-M(OSM) Revenue Market Share by Type (2020-2031)
Figure 63. Asia Recombinant Human Oncostatin-M(OSM) Sales Market Share by Application (2020-2031)
Figure 64. Asia Recombinant Human Oncostatin-M(OSM) Revenue Market Share by Application (2020-2031)
Figure 65. Asia Recombinant Human Oncostatin-M(OSM) Revenue Share by Region (2020-2031)
Figure 66. Asia Recombinant Human Oncostatin-M(OSM) Sales Share by Region (2020-2031)
Figure 67. Japan Recombinant Human Oncostatin-M(OSM) Revenue (2020-2031) & (US$ Million)
Figure 68. South Korea Recombinant Human Oncostatin-M(OSM) Revenue (2020-2031) & (US$ Million)
Figure 69. China Taiwan Recombinant Human Oncostatin-M(OSM) Revenue (2020-2031) & (US$ Million)
Figure 70. Southeast Asia Recombinant Human Oncostatin-M(OSM) Revenue (2020-2031) & (US$ Million)
Figure 71. India Recombinant Human Oncostatin-M(OSM) Revenue (2020-2031) & (US$ Million)
Figure 72. Australia Recombinant Human Oncostatin-M(OSM) Revenue (2020-2031) & (US$ Million)
Figure 73. Middle East, Africa and Latin America Recombinant Human Oncostatin-M(OSM) Sales Market Share by Type (2020-2031)
Figure 74. Middle East, Africa and Latin America Recombinant Human Oncostatin-M(OSM) Revenue Market Share by Type (2020-2031)
Figure 75. Middle East, Africa and Latin America Recombinant Human Oncostatin-M(OSM) Sales Market Share by Application (2020-2031)
Figure 76. Middle East, Africa and Latin America Recombinant Human Oncostatin-M(OSM) Revenue Market Share by Application (2020-2031)
Figure 77. Middle East, Africa and Latin America Recombinant Human Oncostatin-M(OSM) Revenue Share by Country (2020-2031)
Figure 78. Middle East, Africa and Latin America Recombinant Human Oncostatin-M(OSM) Sales Share by Country (2020-2031)
Figure 79. Brazil Recombinant Human Oncostatin-M(OSM) Revenue (2020-2031) & (US$ Million)
Figure 80. Mexico Recombinant Human Oncostatin-M(OSM) Revenue (2020-2031) & (US$ Million)
Figure 81. Turkey Recombinant Human Oncostatin-M(OSM) Revenue (2020-2031) & (US$ Million)
Figure 82. Israel Recombinant Human Oncostatin-M(OSM) Revenue (2020-2031) & (US$ Million)
Figure 83. GCC Countries Recombinant Human Oncostatin-M(OSM) Revenue (2020-2031) & (US$ Million)
Figure 84. Value Chain
Figure 85. Recombinant Human Oncostatin-M(OSM) Production Process
Figure 86. Channels of Distribution (Direct Vs Distribution)
Figure 87. Bottom-up and Top-down Approaches for This Report
Figure 88. Data Triangulation
Figure 89. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
What was the global market size of Recombinant Human Oncostatin-M(OSM) in 2031?
The global market size of Recombinant Human Oncostatin-M(OSM) in 2031 was 198 Million USD.
Which region is expected to have the highest market share?
What is the annual compound growth rate of the global Recombinant Human Oncostatin-M(OSM) market size from 2025 to 2031?
What was the global market size of Recombinant Human Oncostatin-M(OSM) in 2025?
Which companies rank high in the global Recombinant Human Oncostatin-M(OSM) market?
Related Reports
Global Recombinant Human Oncostatin-M(OSM) Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Recombinant Human Oncostatin-M(OSM) market is projected to grow from US$ 118 million in 2025 to US$ 214 million by 2032, at a CAGR of 9.0% (2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2026-03-11
Pages: 179
USD 4900.00
(Single User License)
Global Recombinant Human Oncostatin-M(OSM) Market Research Report 2026
The global Recombinant Human Oncostatin-M(OSM) market was valued at US$ 118 million in 2025 and is anticipated to reach US$ 214 million by 2032, at a CAGR of 9.0% from 2026 to 2032.
Published Date: 2026-03-11
Pages: 128
USD 2900.00
(Single User License)
Global Recombinant Human Oncostatin-M(OSM) Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Recombinant Human Oncostatin-M(OSM) market size was US$ 118 million in 2025 and is forecast to reach a readjusted size of US$ 214 million by 2032 with a CAGR of 9.0% during the forecast period 2026-2032.
Published Date: 2026-03-11
Pages: 109
USD 4250.00
(Single User License)
Recombinant Human Oncostatin-M(OSM)- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Recombinant Human Oncostatin-M(OSM) was estimated to be worth US$ 118 million in 2025 and is projected to reach US$ 214 million, growing at a CAGR of 9.0% from 2026 to 2032.
Published Date: 2026-03-09
Pages: 131
USD 3950.00
(Single User License)
Global Recombinant Human Oncostatin-M(OSM) Market Research Report 2025
The global market for Recombinant Human Oncostatin-M(OSM) was valued at US$ 107 million in the year 2024 and is projected to reach a revised size of US$ 198 million by 2031, growing at a CAGR of 9.0% during the forecast period.
Published Date: 2025-05-10
Pages: 103
USD 2900.00
(Single User License)
Recombinant Human Oncostatin-M(OSM) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Recombinant Human Oncostatin-M(OSM) was estimated to be worth US$ 107 million in 2024 and is forecast to a readjusted size of US$ 198 million by 2031 with a CAGR of 9.0% during the forecast period 2025-2031.
Published Date: 2025-05-10
Pages: 132
USD 3950.00
(Single User License)
Global Recombinant Human Oncostatin-M(OSM) Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Recombinant Human Oncostatin-M(OSM) market size was US$ 107 million in 2024 and is forecast to a readjusted size of US$ 198 million by 2031 with a CAGR of 9.0% during the forecast period 2025-2031.
Published Date: 2025-05-10
Pages: 101
USD 4250.00
(Single User License)
Global Recombinant Human Oncostatin-M(OSM) Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Recombinant Human Oncostatin-M(OSM) market is projected to grow from US$ 118 million in 2025 to US$ 214 million by 2032, at a CAGR of 9.0% (2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2026-03-11
Pages: 179
USD 4900.00 (Single User License)Global Recombinant Human Oncostatin-M(OSM) Market Research Report 2026
The global Recombinant Human Oncostatin-M(OSM) market was valued at US$ 118 million in 2025 and is anticipated to reach US$ 214 million by 2032, at a CAGR of 9.0% from 2026 to 2032.
Published: 2026-03-11
Pages: 128
USD 2900.00 (Single User License)Global Recombinant Human Oncostatin-M(OSM) Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Recombinant Human Oncostatin-M(OSM) market size was US$ 118 million in 2025 and is forecast to reach a readjusted size of US$ 214 million by 2032 with a CAGR of 9.0% during the forecast period 2026-2032.
Published: 2026-03-11
Pages: 109
USD 4250.00 (Single User License)Recombinant Human Oncostatin-M(OSM)- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Recombinant Human Oncostatin-M(OSM) was estimated to be worth US$ 118 million in 2025 and is projected to reach US$ 214 million, growing at a CAGR of 9.0% from 2026 to 2032.
Published: 2026-03-09
Pages: 131
USD 3950.00 (Single User License)Global Recombinant Human Oncostatin-M(OSM) Market Research Report 2025
The global market for Recombinant Human Oncostatin-M(OSM) was valued at US$ 107 million in the year 2024 and is projected to reach a revised size of US$ 198 million by 2031, growing at a CAGR of 9.0% during the forecast period.
Published: 2025-05-10
Pages: 103
USD 2900.00 (Single User License)Recombinant Human Oncostatin-M(OSM) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Recombinant Human Oncostatin-M(OSM) was estimated to be worth US$ 107 million in 2024 and is forecast to a readjusted size of US$ 198 million by 2031 with a CAGR of 9.0% during the forecast period 2025-2031.
Published: 2025-05-10
Pages: 132
USD 3950.00 (Single User License)Global Recombinant Human Oncostatin-M(OSM) Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Recombinant Human Oncostatin-M(OSM) market size was US$ 107 million in 2024 and is forecast to a readjusted size of US$ 198 million by 2031 with a CAGR of 9.0% during the forecast period 2025-2031.
Published: 2025-05-10
Pages: 101
USD 4250.00 (Single User License)
CHOOSE LICENSE TYPE
USD 4900.00
USD 7350.00
USD 9800.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now